Department of Pharmacology & Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
Psychopharmacology (Berl). 2011 Feb;213(2-3):393-401. doi: 10.1007/s00213-010-1928-2. Epub 2010 Jul 21.
Atypical antipsychotic efficacy is often attributed to actions at serotonin-2 (5-HT(2)) and dopamine receptors, indicating a potential benefit of understanding the interplay between these systems. Currently, it is known that 5-HT(2) receptors modulate dopamine release, although the role of specific dopamine receptors in 5-HT(2)-mediated behavior is not well understood.
We examined the role of 5-HT(2A), 5-HT(2C), and dopamine (D1 and D2) receptors in the behavioral response to a 5-HT(2A/2C) agonist (DOI) and 5-HT(2A/2C) antagonist (SR46349B).
Effects were assessed by measuring rabbit head bobs (previously characterized as 5-HT(2A) receptor-mediated) and body shakes (5-HT(2C)-mediated).
As expected, DOI produced head bobs and body shakes, and these DOI-elicited behaviors were attenuated by the SR46349B pretreatment. Unexpectedly, SR46349B also induced head bobs when administered alone. However, SR46349B-elicited head bobs are distinguishable from those produced by DOI since the 5-HT(2A) antagonist, ketanserin, only attenuated DOI-elicited head bobs. Conversely, 5-HT(2C) ligands (SB242084 and SB206553) inhibited SR46349B but not DOI-induced head bobs. Furthermore, when administered alone, SB206553 (a 5-HT(2C) inverse agonist) produced head bobs, indicating the behavior can be either 5-HT(2A) or 5-HT(2C) mediated. Next, it was revealed that D1 and D2 receptors play a role in DOI-elicited head bobs, but only D1 receptors are required for SR46349B-elicited head bobs.
5-HT(2A) receptor agonism and 5-HT(2C) inverse agonism produce the same behavior, likely due to similar downstream actions at D1 receptors. Consequently, 5-HT(2C) agonism or D1 agonism may be effective therapies for disorders, such as schizophrenia, currently being treated with 5-HT(2A) antagonists.
非典型抗精神病药的疗效通常归因于对 5-羟色胺-2(5-HT(2))和多巴胺受体的作用,这表明了解这些系统相互作用的潜在益处。目前,已知 5-HT(2)受体调节多巴胺的释放,尽管特定的多巴胺受体在 5-HT(2)介导的行为中的作用还不是很清楚。
我们研究了 5-HT(2A)、5-HT(2C)和多巴胺(D1 和 D2)受体在对 5-HT(2A/2C)激动剂(DOI)和 5-HT(2A/2C)拮抗剂(SR46349B)的行为反应中的作用。
通过测量兔子的头摆动(以前被认为是 5-HT(2A)受体介导的)和身体抖动(5-HT(2C)介导的)来评估效应。
正如预期的那样,DOI 产生了头摆动和身体抖动,而 SR46349B 的预处理减弱了 DOI 诱发的这些行为。出乎意料的是,SR46349B 单独给药也会引起头摆动。然而,SR46349B 诱导的头摆动与 DOI 产生的头摆动不同,因为 5-HT(2A)拮抗剂酮色林仅减弱了 DOI 诱导的头摆动。相反,5-HT(2C)配体(SB242084 和 SB206553)抑制了 SR46349B 但不抑制 DOI 诱导的头摆动。此外,当单独给药时,SB206553(一种 5-HT(2C)反向激动剂)产生了头摆动,这表明该行为可能是 5-HT(2A)或 5-HT(2C)介导的。接下来,结果表明 D1 和 D2 受体在 DOI 诱导的头摆动中起作用,但只有 D1 受体参与 SR46349B 诱导的头摆动。
5-HT(2A)受体激动剂和 5-HT(2C)反向激动剂产生相同的行为,可能是由于 D1 受体的下游作用相似。因此,5-HT(2C)激动剂或 D1 激动剂可能是治疗精神分裂症等疾病的有效疗法,目前正在使用 5-HT(2A)拮抗剂治疗这些疾病。